# Q2ï¼šå°ç£ä¸‰é«˜é æ¸¬ç›¸é—œæ–‡ç»å›é¡§

## ğŸ“‹ æ–‡æª”ç‹€æ…‹

**æœ€å¾Œæ›´æ–°**ï¼š2025-11-11
**ç”¨é€”**ï¼šæ•´ç†å°ç£åŠè¯äººåœ°å€ä¸‰é«˜é æ¸¬çš„æ©Ÿå™¨å­¸ç¿’ç ”ç©¶
**é‡é»**ï¼šç¸±å‘è³‡æ–™ï¼ˆlongitudinal dataï¼‰èˆ‡æ™‚åºç‰¹å¾µé æ¸¬æ¨¡å‹

---

## ç›®éŒ„

1. [é–±è®€ç‹€æ…‹ç¸½è¦½](#é–±è®€ç‹€æ…‹ç¸½è¦½)
2. [é«˜è¡€å£“é æ¸¬ç ”ç©¶](#ä¸€é«˜è¡€å£“é æ¸¬hypertension-prediction)
3. [ç³–å°¿ç—…é æ¸¬ç ”ç©¶](#äºŒç³–å°¿ç—…é æ¸¬diabetes-prediction)
4. [é«˜è¡€è„‚é æ¸¬ç ”ç©¶](#ä¸‰é«˜è¡€è„‚é æ¸¬dyslipidemiahyperlipidemia-prediction)
5. [ä»£è¬ç—‡å€™ç¾¤ç ”ç©¶](#å››ä»£è¬ç—‡å€™ç¾¤é æ¸¬metabolic-syndrome)
6. [èˆ‡æœ¬ç ”ç©¶çš„é—œè¯](#äº”èˆ‡æœ¬ç ”ç©¶çš„é—œè¯æ€§åˆ†æ)
7. [ç ”ç©¶ç¼ºå£èˆ‡è²¢ç»](#å…­ç ”ç©¶ç¼ºå£research-gap)
8. [æ–¹æ³•è«–å•Ÿç¤º](#ä¸ƒæ–¹æ³•è«–å•Ÿç¤º)
9. [åƒè€ƒæ–‡ç»](#å…«åƒè€ƒæ–‡ç»æ¸…å–®)

---

## é–±è®€ç‹€æ…‹ç¸½è¦½

### âœ… å·²å®Œæ•´åˆ†æï¼ˆæœ‰æ·±åº¦è§£ææ–‡æª”ï¼‰

| ç·¨è™Ÿ | è«–æ–‡ | ä½œè€… | ç–¾ç—… | ç‹€æ…‹ | æ–‡æª”ä½ç½® |
|------|------|------|------|------|---------|
| 3 | å°ç£ç¬¬äºŒå‹ç³–å°¿ç—…ç™¼ç—…é æ¸¬ | Liu et al. (2024) | ç³–å°¿ç—… | âœ… å·²å®Œæ•´åˆ†æ | [æ·±åº¦è§£æ](../literature_notes/Liu_2024_TCVGH_Diabetes_Prediction_æ·±åº¦è§£æ.md) |

### âš ï¸ å·²æ•´ç†æ‘˜è¦ï¼ˆå¾…æ·±å…¥åˆ†æï¼‰

| ç·¨è™Ÿ | è«–æ–‡ | ä½œè€… | ç–¾ç—… | ç‹€æ…‹ | PDFä½ç½® |
|------|------|------|------|------|---------|
| 1 | éš±åŒ¿æ€§é«˜è¡€å£“é æ¸¬ | Hung et al. (2021) | é«˜è¡€å£“ | âš ï¸ æœ‰PDFï¼Œå¾…æ·±å…¥åˆ†æ | [fcvm-08-778306.pdf](../references/fcvm-08-778306.pdf) |
| 4 | å‰é©…ç³–å°¿ç—…é æ¸¬ï¼ˆé›™æ¡†æ¶ï¼‰| Dual Framework (2025) | ç³–å°¿ç—… | ğŸ“Œ **é«˜å„ªå…ˆç´šå¾…è®€** | å¾…ä¸‹è¼‰ |

### ğŸ“‹ åŸºæœ¬è³‡è¨Šå·²æ•´ç†

| ç·¨è™Ÿ | è«–æ–‡ | ä½œè€… | ç–¾ç—… | å‚™è¨» |
|------|------|------|------|------|
| 2 | å°ç£é«˜è¡€å£“é¢¨éšªé æ¸¬ | Chien et al. (2011) | é«˜è¡€å£“ | æ—©æœŸç ”ç©¶ |
| 5 | ç³–å°¿ç—…ç¥ç¶“ç¶²è·¯é æ¸¬ | Chen & Huang (2023) | ç³–å°¿ç—… | - |
| 6-7 | é«˜è¡€è„‚é æ¸¬ | åœ‹éš›ç ”ç©¶ | é«˜è¡€è„‚ | å°ç£ç ”ç©¶è¼ƒå°‘ |
| 8-10 | ä»£è¬ç—‡å€™ç¾¤ | å°ç£ç ”ç©¶ | ä»£è¬ç—‡å€™ç¾¤ | - |

---

## ä¸€ã€é«˜è¡€å£“é æ¸¬ï¼ˆHypertension Predictionï¼‰

### ç ”ç©¶ 1ï¼šéš±åŒ¿æ€§é«˜è¡€å£“çš„æ©Ÿå™¨å­¸ç¿’é æ¸¬ âš ï¸

**åŸºæœ¬è³‡è¨Š**ï¼š
- **ä½œè€…**ï¼šHung et al. (2021)
- **æœŸåˆŠ**ï¼šFrontiers in Cardiovascular Medicine, 8:778306
- **DOI**ï¼š[10.3389/fcvm.2021.778306](https://doi.org/10.3389/fcvm.2021.778306)
- **PDF**ï¼š[fcvm-08-778306.pdf](../references/fcvm-08-778306.pdf)
- **ç‹€æ…‹**ï¼šâš ï¸ æœ‰PDFï¼Œå¾…æ·±å…¥åˆ†æ

**ç ”ç©¶è¨­è¨ˆ**ï¼š
- **è³‡æ–™ä¾†æº**ï¼šå°ç£å…­å®¶é†«å­¸ä¸­å¿ƒï¼ˆ2004-2005ï¼‰+ å°åŒ—æ¦®ç¸½ï¼ˆ2012-2020ï¼‰
- **æ¨£æœ¬æ•¸**ï¼šCohort 1: 970ä½ï¼›Cohort 2: 416ä½
- **ç ”ç©¶ç›®æ¨™**ï¼šé æ¸¬éš±åŒ¿æ€§é«˜è¡€å£“ï¼ˆMasked Hypertension, MHï¼‰å’Œéš±åŒ¿æ€§æœªæ§åˆ¶é«˜è¡€å£“ï¼ˆMUCHï¼‰
- **è¿½è¹¤é¡å‹**ï¼šæ©«æ–·é¢ç ”ç©¶ï¼ˆå–®æ¬¡å°±è¨ºï¼‰

**æ–¹æ³•**ï¼š
- **ç‰¹å¾µæ•¸**ï¼š33å€‹è‡¨åºŠç‰¹å¾µ
  - äººå£çµ±è¨ˆ
  - è¡€å£“åƒæ•¸ï¼ˆDBP, MAP, SBP, PPï¼‰
  - é™å£“è—¥ç‰©ï¼ˆbeta-blockerï¼‰
  - ç”ŸåŒ–æŒ‡æ¨™ï¼ˆHDL-Cï¼‰
- **æ¨¡å‹**ï¼šLogistic Regressionã€Random Forestã€XGBoostã€ANN
- **è³‡æ–™è™•ç†**ï¼šSMOTE-NC è™•ç†é¡åˆ¥ä¸å¹³è¡¡

**ä¸»è¦ç™¼ç¾**ï¼š
- **æœ€ä½³æ¨¡å‹**ï¼šRandom Forest
  - Internal AUC = 0.851
  - External AUC = 0.837
- **é—œéµç‰¹å¾µ**ï¼ˆ6å€‹ï¼‰ï¼šoffice DBP, MAP, SBP, PP, beta-blocker, HDL-C
- **æ€§èƒ½**ï¼šSensitivity = 1.000, NPV = 1.000

**èˆ‡æœ¬ç ”ç©¶çš„é—œè¯**ï¼š
- âœ… å°ç£æœ¬åœŸè³‡æ–™
- âœ… ä½¿ç”¨è¡€å£“åƒæ•¸ + ç”ŸåŒ–æŒ‡æ¨™ï¼ˆHDL-Cï¼‰
- âœ… é©—è­‰ RFã€XGBoost åœ¨å°ç£è³‡æ–™çš„æœ‰æ•ˆæ€§
- âŒ æ©«æ–·é¢ç ”ç©¶ï¼Œéç¸±å‘é æ¸¬
- ğŸ” **å¾…æ·±å…¥åˆ†æ**ï¼šç‰¹å¾µé¸æ“‡æ–¹æ³•ã€æ¨¡å‹èª¿å„ªç­–ç•¥

---

### ç ”ç©¶ 2ï¼šå°ç£é«˜è¡€å£“é¢¨éšªé æ¸¬æ¨¡å‹

**åŸºæœ¬è³‡è¨Š**ï¼š
- **ä½œè€…**ï¼šChien et al. (2011)
- **æœŸåˆŠ**ï¼šJournal of Human Hypertension
- **ç ”ç©¶ç›®æ¨™**ï¼šç‚ºå°ç£è¯äººæ—ç¾¤å»ºç«‹æ–°ç™¼é«˜è¡€å£“çš„é¢¨éšªé æ¸¬æ¨¡å‹
- **ç‹€æ…‹**ï¼šæ—©æœŸç ”ç©¶ï¼Œè³‡æ–™æœªè©³ç´°ç²å–

---

## äºŒã€ç³–å°¿ç—…é æ¸¬ï¼ˆDiabetes Predictionï¼‰

### ç ”ç©¶ 3ï¼šå°ç£ç¬¬äºŒå‹ç³–å°¿ç—…ç™¼ç—…é æ¸¬ âœ…

**åŸºæœ¬è³‡è¨Š**ï¼š
- **ä½œè€…**ï¼šLiu et al. (2024)
- **æœŸåˆŠ**ï¼šDiagnostics, 15(1), 72
- **DOI**ï¼š[10.3390/diagnostics15010072](https://doi.org/10.3390/diagnostics15010072)
- **PDF**ï¼š[diagnostics-15-00072.pdf](../references/diagnostics-15-00072.pdf)
- **ç‹€æ…‹**ï¼šâœ… å·²å®Œæ•´åˆ†æ

**ç ”ç©¶è¨­è¨ˆ**ï¼š
- **è³‡æ–™ä¾†æº**ï¼šå°ä¸­æ¦®æ°‘ç¸½é†«é™¢é›»å­ç—…æ­·ï¼ˆ2003-2022ï¼‰
- **æ¨£æœ¬æ•¸**ï¼š6,687ä½ç›¸å°å¥åº·çš„æˆå¹´äºº
- **è¿½è¹¤æ™‚é–“**ï¼š10å¹´ç¸±å‘ç ”ç©¶
- **è³‡æ–™ä¸å¹³è¡¡**ï¼šClass 0 (98.9%) vs Class 1 (1.1%)ï¼Œæ¯”ä¾‹ 92:1

**æ–¹æ³•**ï¼š
- **ç‰¹å¾µæ•¸**ï¼š33å€‹è‡¨åºŠç‰¹å¾µ
- **æ¨¡å‹**ï¼šLogistic Regressionã€Random Forestã€XGBoost

**ä¸»è¦ç™¼ç¾**ï¼š
- **æ¨¡å‹æ€§èƒ½**ï¼š
  - Random Forestï¼šAccuracy 99%, AUC 0.74
  - Logistic Regressionï¼šAccuracy 99%, AUC 0.90
  - XGBoostï¼šAccuracy 98%, **AUC 0.93** â­ï¼ˆæœ€ä½³ï¼‰
- **é—œéµç‰¹å¾µ**ï¼š
  1. HbA1cï¼ˆç³–åŒ–è¡€è‰²ç´ ï¼‰
  2. Fasting Blood Glucoseï¼ˆç©ºè…¹è¡€ç³–ï¼‰
  3. Weightï¼ˆé«”é‡ï¼‰
  4. Free Thyroxine (fT4)ï¼ˆæ¸¸é›¢ç”²ç‹€è…ºç´ ï¼‰â­ é¦–æ¬¡ç™¼ç¾
  5. Triglyceridesï¼ˆä¸‰é…¸ç”˜æ²¹é…¯ï¼‰

**èˆ‡æœ¬ç ”ç©¶çš„é—œè¯**ï¼š
- âœ… å°ç£æœ¬åœŸè³‡æ–™ï¼Œäººå£ç‰¹æ€§ç›¸è¿‘
- âœ… 10å¹´ç¸±å‘è¿½è¹¤è¨­è¨ˆ
- âœ… é«˜æº–ç¢ºç‡å¯ä½œç‚º benchmarkï¼ˆAUC > 0.90ï¼‰
- âœ… ç‰¹å¾µé¸æ“‡å¯ä¾›åƒè€ƒ
- âœ… è™•ç†æ¥µåº¦ä¸å¹³è¡¡è³‡æ–™çš„ç¶“é©—

**è©³ç´°æ–‡æª”**ï¼š
- [æ·±åº¦è§£æ](../literature_notes/Liu_2024_TCVGH_Diabetes_Prediction_æ·±åº¦è§£æ.md)
- ç°¡å ±æª”ï¼šmeeting15_21138X006_ç´€ä¼¯å–¬_wVBA.pptm (å·²å ±å‘Šå®Œæˆ)

---

### ç ”ç©¶ 4ï¼šå°ç£é’å¹´ç”·æ€§è¡€ç³–è®ŠåŒ–èˆ‡å‰é©…ç³–å°¿ç—…é æ¸¬ ğŸ“Œ

**åŸºæœ¬è³‡è¨Š**ï¼š
- **ä½œè€…**ï¼šDual Machine Learning Framework (2025)
- **è³‡æ–™ä¾†æº**ï¼šTaiwan Biobank
- **ç‹€æ…‹**ï¼šğŸ“Œ **é«˜å„ªå…ˆç´šå¾…è®€**ï¼ˆèˆ‡æœ¬ç ”ç©¶é«˜åº¦ç›¸é—œï¼‰

**ç ”ç©¶è¨­è¨ˆ**ï¼š
- **æ¨£æœ¬æ•¸**ï¼š6,247ä½ 18-35æ­²å°ç£ç”·æ€§
- **è¿½è¹¤æ™‚é–“**ï¼šå¹³å‡ 5.9å¹´

**æ–¹æ³•**ï¼š
- **é›™æ©Ÿå™¨å­¸ç¿’æ¡†æ¶**ï¼š
  1. é æ¸¬è¡€ç³–è®ŠåŒ–é‡ï¼ˆÎ´-FPGï¼‰â† **èˆ‡æœ¬ç ”ç©¶çš„ Î” ç‰¹å¾µæ¦‚å¿µç›¸ä¼¼** â­
  2. åˆ†é¡å‰é©…ç³–å°¿ç—…é¢¨éšª
- **æ¨¡å‹**ï¼šRandom Forestã€Stochastic Gradient Boostingã€XGBoostã€Elastic Net
- **å¯è§£é‡‹æ€§**ï¼šä½¿ç”¨ SHAP
- **ç©©å¥æ€§**ï¼š10æ¬¡é‡è¤‡è¨“ç·´æ¸¬è©¦

**ä¸»è¦ç™¼ç¾**ï¼š
- Î´-FPG é æ¸¬ï¼šXGBoost å’Œ Random Forest è¡¨ç¾æœ€ä½³
- å‰é©…ç³–å°¿ç—…åˆ†é¡ï¼šAUC ç”·æ€§ 0.76, å¥³æ€§ 0.80
- å¼·èª¿å¹´é½¡å’Œæ€§åˆ¥å·®ç•°çš„é‡è¦æ€§

**èˆ‡æœ¬ç ”ç©¶çš„é—œè¯**ï¼š
- âœ…âœ… **é«˜åº¦ç›¸é—œ**ï¼šåŒæ¨£ä½¿ç”¨ç¸±å‘è³‡æ–™é æ¸¬æœªä¾†ç–¾ç—…é¢¨éšª
- âœ…âœ… **è®ŠåŒ–é‡ç‰¹å¾µ**ï¼šÎ´-FPG èˆ‡æˆ‘å€‘çš„ Î” ç‰¹å¾µè¨­è¨ˆç›¸åŒ
- âœ… é›™æ¡†æ¶è¨­è¨ˆï¼ˆé€£çºŒå€¼é æ¸¬ + äºŒå…ƒåˆ†é¡ï¼‰å¯å€Ÿé¡
- âœ… SHAP è§£é‡‹æ€§æ–¹æ³•å¯æ‡‰ç”¨
- âœ… é‡è¤‡è¨“ç·´è©•ä¼°ç©©å®šæ€§çš„åšæ³•å€¼å¾—æ¡ç”¨

**ä¸‹ä¸€æ­¥**ï¼šMeeting 17 å„ªå…ˆæ·±å…¥ç ”ç©¶æ­¤è«–æ–‡

---

### ç ”ç©¶ 5ï¼šå°ç£ç³–å°¿ç—…ç™¼ç—…é æ¸¬ï¼ˆç¥ç¶“ç¶²è·¯ï¼‰

**åŸºæœ¬è³‡è¨Š**ï¼š
- **ä½œè€…**ï¼šChen & Huang (2023)
- **æœŸåˆŠ**ï¼šJournal of Personalized Medicine
- **è³‡æ–™ä¾†æº**ï¼šå°ç£æ‚£è€…è³‡æ–™

**æ–¹æ³•**ï¼š
- Microsoft Machine Learning Studio
- å¤šç¨®ç¥ç¶“ç¶²è·¯æ¨¡å‹æ¯”è¼ƒ

**ä¸»è¦ç™¼ç¾**ï¼š
- Two-class Boosted Decision Tree è¡¨ç¾æœ€ä½³
- AUC = 0.991

**èˆ‡æœ¬ç ”ç©¶çš„é—œè¯**ï¼š
- è­‰å¯¦æ·±åº¦å­¸ç¿’åœ¨å°ç£ç³–å°¿ç—…é æ¸¬çš„æœ‰æ•ˆæ€§
- æ¥µé«˜çš„ AUC å€¼é¡¯ç¤ºå•é¡Œå¯è¡Œæ€§

---

## ä¸‰ã€é«˜è¡€è„‚é æ¸¬ï¼ˆDyslipidemia/Hyperlipidemia Predictionï¼‰

### å°ç£ç ”ç©¶ç¾ç‹€

âš ï¸ **å°ç£é«˜è¡€è„‚é æ¸¬ç ”ç©¶è¼ƒå°‘**ï¼Œä¸»è¦ç‚ºåœ‹éš›ç ”ç©¶

### åœ‹éš›ç ”ç©¶åƒè€ƒ

#### ç ”ç©¶ 6ï¼šè¡€è„‚ç•°å¸¸é æ¸¬ï¼ˆä¼Šæœ—ï¼‰

- **è³‡æ–™ä¾†æº**ï¼šä¼Šæœ— East Azerbaijan Province
- **æ–¹æ³•**ï¼šMultilayer Perceptron (MLP) è¡¨ç¾æœ€ä½³
- **ç™¼ç¾**ï¼šIRï¼ˆèƒ°å³¶ç´ é˜»æŠ—ï¼‰ç›¸é—œæŒ‡æ¨™å¦‚ TyG index æ˜¯é‡è¦é æ¸¬å› å­

#### ç ”ç©¶ 7ï¼šLDL-C é æ¸¬ï¼ˆéŸ“åœ‹ï¼‰

- **è³‡æ–™ä¾†æº**ï¼šKNHANES è³‡æ–™
- **æ–¹æ³•**ï¼šæ¯”è¼ƒ ML æ¨¡å‹èˆ‡å‚³çµ±å…¬å¼
- **ç™¼ç¾**ï¼š
  - Random Forest å’Œ XGBoost æœ€ä½³ï¼ˆRÂ² = 0.94ï¼‰
  - ML åœ¨é«˜ä¸‰é…¸ç”˜æ²¹é…¯æƒ…æ³ä¸‹ä»ä¿æŒé«˜æº–ç¢ºç‡

### å°ç£è¡€è„‚æŒ‡å¼•

- 2022 Taiwan Lipid Guidelines for Primary Prevention
- 2017 Taiwan Lipid Guidelines for High Risk Patients
- å¯ä½œç‚ºè‡¨åºŠæ¨™æº–å’Œè©•ä¼°åŸºæº–

---

## å››ã€ä»£è¬ç—‡å€™ç¾¤é æ¸¬ï¼ˆMetabolic Syndromeï¼‰

### ç ”ç©¶ 8ï¼šå°ç£æˆäººä»£è¬ç—‡å€™ç¾¤åš´é‡åº¦è©•åˆ†

**åŸºæœ¬è³‡è¨Š**ï¼š
- **æ¨™é¡Œ**ï¼šAn Application of MS Severity Scores (2020)
- **è³‡æ–™ä¾†æº**ï¼šMajor Health Screening Center, Taiwan
- **æ¨£æœ¬æ•¸**ï¼š71,108ä½ 20-64æ­²åƒèˆ‡è€…

**æ–¹æ³•**ï¼š
- ä½¿ç”¨ Principal Component Analysis (PCA) å»ºç«‹ MetS-Z score
- ä¾æ€§åˆ¥å’Œå¹´é½¡åˆ†çµ„ï¼ˆ20-34, 35-49, 50-64æ­²ï¼‰

**ä¸»è¦ç™¼ç¾**ï¼š
- MetS ç››è¡Œç‡åœ¨å°ç£ 12å¹´å…§å¾ 13.6% æˆé•·è‡³ 25.5%
- é€£çºŒè©•åˆ†æ¯”äºŒå…ƒè¨ºæ–·æ›´èƒ½åæ˜ é¢¨éšªç¨‹åº¦
- èˆ‡ç”Ÿæ´»æ–¹å¼å› ç´ ï¼ˆé‹å‹•ã€é£²é…’ã€å¸è¸ï¼‰é«˜åº¦ç›¸é—œ

---

### ç ”ç©¶ 9ï¼šå°ç£æˆäººä»£è¬ç—‡å€™ç¾¤é¢¨éšªå› å­è©•ä¼°

**æ–¹æ³•**ï¼šDecision Tree Algorithm

**ä¸»è¦ç™¼ç¾**ï¼š
- Triglycerides (TG) æ˜¯æœ€é‡è¦çš„ root node
- Waist Circumference (WC) æ˜¯æ¬¡è¦é—œéµå› å­
- ä¸­é«˜é½¡æ—ç¾¤çš„ TG å’Œ WC æ˜¯é é˜² MetS çš„é—œéµ

---

### ç ”ç©¶ 10ï¼šå°ç£äººå·¥ç¥ç¶“ç¶²è·¯é æ¸¬ä»£è¬ç—‡å€™ç¾¤

**ç ”ç©¶è¨­è¨ˆ**ï¼š
- **è³‡æ–™ä¾†æº**ï¼šå°ç£å¥æª¢æ©Ÿæ§‹ï¼ˆ2006-2014ï¼‰
- **æ¨£æœ¬æ•¸**ï¼š27,415ä½å—è©¦è€…
- **è¿½è¹¤**ï¼šä¸‰å€‹éšæ®µçš„é‡è¤‡æ¸¬é‡

**æ–¹æ³•**ï¼š
- Artificial Neural Network (ANN)
- Over-sampling technique (SMOTE)

**ä¸»è¦ç™¼ç¾**ï¼š
- AUC é” 0.93
- Over-sampling æå‡æ•æ„Ÿåº¦å’Œ F2 measure
- MetS ç››è¡Œç‡ï¼šStage 1 (18.3%), Stage 2 (24.6%), Stage 3 (30.1%)

---

## äº”ã€èˆ‡æœ¬ç ”ç©¶çš„é—œè¯æ€§åˆ†æ

### ç¶œåˆæ¯”è¼ƒè¡¨

| ç ”ç©¶ | åœ‹å®¶ | ç–¾ç—… | æ¨£æœ¬æ•¸ | è¿½è¹¤æ™‚é–“ | æœ€ä½³æ¨¡å‹ | AUC/æº–ç¢ºç‡ | é—œéµç‰¹å¾µ | é–±è®€ç‹€æ…‹ |
|------|------|------|--------|---------|---------|-----------|---------|---------|
| Hung 2021 | å°ç£ | éš±åŒ¿æ€§é«˜è¡€å£“ | 970+416 | æ©«æ–·é¢ | RF | 0.851/0.837 | DBP, MAP, SBP, PP, beta-blocker, HDL-C | âš ï¸ å¾…æ·±å…¥åˆ†æ |
| Liu 2024 | å°ç£ | ç¬¬äºŒå‹ç³–å°¿ç—… | 6,687 | 10å¹´ | XGBoost | 0.93 | HbA1c, FBG, Weight, fT4, TG | âœ… å·²å®Œæ•´åˆ†æ |
| Dual 2025 | å°ç£ | å‰é©…ç³–å°¿ç—… | 6,247 | 5.9å¹´ | XGBoost/RF | 0.76-0.80 | Î´-FPG, Age, BMI | ğŸ“Œ é«˜å„ªå…ˆç´šå¾…è®€ |
| Chen 2023 | å°ç£ | ç³–å°¿ç—… | N/A | N/A | Boosted DT | 0.991 | N/A | ğŸ“‹ åŸºæœ¬è³‡è¨Š |
| MS 2020 | å°ç£ | ä»£è¬ç—‡å€™ç¾¤ | 71,108 | æ©«æ–·é¢ | PCA | N/A | WC, FPG, BP, TG, HDL-C | ğŸ“‹ åŸºæœ¬è³‡è¨Š |
| ANN MetS | å°ç£ | ä»£è¬ç—‡å€™ç¾¤ | 27,415 | 3 stages | ANN | 0.93 | ç¤¾ç¶“åœ°ä½+ç”Ÿæ´»æ–¹å¼ | ğŸ“‹ åŸºæœ¬è³‡è¨Š |

### é«˜åº¦ç›¸é—œçš„ç ”ç©¶ï¼ˆå„ªå…ˆåƒè€ƒï¼‰

#### 1. Liu et al. 2024ï¼ˆå°ç£ç³–å°¿ç—…é æ¸¬ï¼‰âœ…
**ç›¸ä¼¼åº¦**ï¼šâ­â­â­â­â­
- âœ… å°ç£æœ¬åœŸè³‡æ–™
- âœ… 10å¹´ç¸±å‘è¿½è¹¤
- âœ… è¡€æ¶²æª¢é©—æ•¸æ“šï¼ˆHbA1c, FBG, TGï¼‰
- âœ… å¯ä½œç‚ºç³–å°¿ç—…é æ¸¬çš„ baseline
- âœ… å·²å®Œæ•´åˆ†æï¼Œå¯ç›´æ¥å¼•ç”¨

#### 2. Dual Framework 2025ï¼ˆå°ç£å‰é©…ç³–å°¿ç—…ï¼‰ğŸ“Œ
**ç›¸ä¼¼åº¦**ï¼šâ­â­â­â­â­
- âœ…âœ… **ç¸±å‘è¡€ç³–è®ŠåŒ–é æ¸¬**ï¼ˆÎ´-FPGï¼‰
- âœ…âœ… **èˆ‡æœ¬ç ”ç©¶çš„ Î” ç‰¹å¾µæ¦‚å¿µç›¸åŒ**
- âœ… é›™æ©Ÿå™¨å­¸ç¿’æ¡†æ¶è¨­è¨ˆ
- âœ… SHAP è§£é‡‹æ€§æ–¹æ³•
- âœ… é‡è¤‡å¯¦é©—è©•ä¼°ç©©å®šæ€§
- ğŸ“Œ **Meeting 17 å„ªå…ˆæ·±å…¥ç ”ç©¶**

#### 3. Hung et al. 2021ï¼ˆå°ç£éš±åŒ¿æ€§é«˜è¡€å£“ï¼‰âš ï¸
**ç›¸ä¼¼åº¦**ï¼šâ­â­â­â­
- âœ… å°ç£å¤šä¸­å¿ƒè³‡æ–™
- âœ… è¡€å£“åƒæ•¸ + ç”ŸåŒ–æŒ‡æ¨™ï¼ˆHDL-Cï¼‰
- âœ… å¤–éƒ¨é©—è­‰è¨­è¨ˆ
- âœ… Random Forest å„ªç•°è¡¨ç¾
- âš ï¸ å¾…æ·±å…¥åˆ†æ

### å¯å€Ÿé‘‘çš„ç ”ç©¶è¨­è¨ˆ

#### 1. ç‰¹å¾µå·¥ç¨‹
- **è®ŠåŒ–é‡ç‰¹å¾µï¼ˆÎ”ç‰¹å¾µï¼‰**ï¼šDual Framework 2025 çš„ Î´-FPG
- **æ™‚é–“é–“éš”ç‰¹å¾µ**ï¼šè¿½è¹¤æ™‚é–“ä½œç‚ºç‰¹å¾µ
- **è—¥ç‰©ä½¿ç”¨ç‰¹å¾µ**ï¼šHung 2021 çš„ beta-blocker

#### 2. æ¨¡å‹é¸æ“‡
- **Random Forestã€XGBoost** åœ¨å°ç£è³‡æ–™è¡¨ç¾ç©©å®š
- **Ensemble æ–¹æ³•**æ™®éå„ªæ–¼å–®ä¸€æ¨¡å‹
- **ANN/MLP** åœ¨è™•ç†éç·šæ€§é—œä¿‚æ™‚æœ‰å„ªå‹¢

#### 3. è©•ä¼°æŒ‡æ¨™
- **AUC-ROC** ä½œç‚ºä¸»è¦æŒ‡æ¨™ï¼ˆè™•ç†ä¸å¹³è¡¡è³‡æ–™ï¼‰
- **Sensitivity/Specificity/NPV/PPV** å…¨é¢è©•ä¼°
- **å¤–éƒ¨é©—è­‰**çš„å¿…è¦æ€§

---

## å…­ã€ç ”ç©¶ç¼ºå£ï¼ˆResearch Gapï¼‰

### æœ¬ç ”ç©¶å¡«è£œçš„ç¼ºå£

1. **å¤šæ¨™ç±¤åŒæ™‚é æ¸¬** â­
   - ç¾æœ‰æ–‡ç»ï¼šå¤šç‚ºå–®ä¸€ç–¾ç—…é æ¸¬
   - æœ¬ç ”ç©¶ï¼šåŒæ™‚é æ¸¬ä¸‰é«˜ï¼ˆé«˜è¡€å£“ã€é«˜è¡€ç³–ã€é«˜è¡€è„‚ï¼‰

2. **ç¸±å‘æ™‚åºç‰¹å¾µ** â­
   - ç¾æœ‰æ–‡ç»ï¼šå°‘æ•¸ç ”ç©¶ä½¿ç”¨è®ŠåŒ–é‡ï¼ˆå¦‚ Dual Framework 2025 çš„ Î´-FPGï¼‰
   - æœ¬ç ”ç©¶ï¼šçµåˆ Tâ‚ å’Œ Tâ‚‚ çš„è®ŠåŒ–é‡é€²è¡Œ Tâ‚ƒ é æ¸¬

3. **å°ç£æœ¬åœŸä¸‰é«˜ç¶œåˆç ”ç©¶** â­
   - ç¾æœ‰æ–‡ç»ï¼šå°ç£ç ”ç©¶å¤šå°ˆæ³¨å–®ä¸€ç–¾ç—…
   - æœ¬ç ”ç©¶ï¼šæ•´åˆä¸‰ç¨®ä»£è¬ç–¾ç—…çš„é æ¸¬æ¨¡å‹

4. **å¤šè³‡æ–™é›†é©—è­‰**
   - ç¾æœ‰æ–‡ç»ï¼šå¤šç‚ºå–®ä¸€è³‡æ–™é›†
   - æœ¬ç ”ç©¶ï¼šä½¿ç”¨ä¸­åœ‹å’ŒåŠ æ‹¿å¤§è³‡æ–™é›†äº¤å‰é©—è­‰

### æ¨¡å‹æ€§èƒ½åŸºæº–ï¼ˆBenchmarkï¼‰

æ ¹æ“šå°ç£æ–‡ç»ï¼Œæ€§èƒ½åŸºæº–ï¼š

| ç–¾ç—… | AUC ç¯„åœ | æº–ç¢ºç‡ | åƒè€ƒæ–‡ç» |
|------|---------|--------|---------|
| **é«˜è¡€å£“** | 0.75-0.85 | - | Hung 2021 |
| **ç³–å°¿ç—…** | 0.76-0.99 | 98-99% | Liu 2024, Chen 2023 |
| **ä»£è¬ç—‡å€™ç¾¤** | 0.90-0.93 | - | ANN MetS 2006-14 |

**æœ¬ç ”ç©¶ç›®æ¨™**ï¼š
- AUC-ROC > 0.75
- F1-Score > 0.65
- Recall > 0.65

é€™äº›ç›®æ¨™èˆ‡æ–‡ç»åŸºæº–ä¸€è‡´ï¼Œå…·æœ‰å¯é”æˆæ€§ã€‚

---

## ä¸ƒã€æ–¹æ³•è«–å•Ÿç¤º

### è³‡æ–™è™•ç†

1. **ç¼ºå¤±å€¼è™•ç†**ï¼šMean imputation
2. **é¡åˆ¥ä¸å¹³è¡¡**ï¼šSMOTEã€SMOTE-NCã€Over-sampling
3. **æ¨™æº–åŒ–**ï¼šZ-score normalizationï¼ˆç‰¹åˆ¥åœ¨ LR å’Œ ANNï¼‰

### ç‰¹å¾µé¸æ“‡

1. **LASSO regression**
2. **Random Forest feature importance**
3. **SHAP values**ï¼ˆå¯è§£é‡‹æ€§ï¼‰
4. **Mutual Information**

### æ¨¡å‹é©—è­‰

1. **å…§éƒ¨é©—è­‰**ï¼šè¨“ç·´é›†/é©—è­‰é›†/æ¸¬è©¦é›†åˆ†å‰²ï¼ˆ70/15/15ï¼‰
2. **å¤–éƒ¨é©—è­‰**ï¼šä¸åŒæ™‚æœŸæˆ–ä¸åŒé†«é™¢çš„è³‡æ–™
3. **äº¤å‰é©—è­‰**ï¼š10-fold cross-validation
4. **é‡è¤‡å¯¦é©—**ï¼šå¤šæ¬¡éš¨æ©Ÿç¨®å­ç¢ºä¿ç©©å®šæ€§

### å¯è§£é‡‹æ€§

1. **SHAP (SHapley Additive exPlanations)**ï¼šå…¨å±€å’Œå±€éƒ¨è§£é‡‹
2. **Feature Importance Ranking**
3. **Decision Tree Visualization**

---

## å…«ã€åƒè€ƒæ–‡ç»æ¸…å–®

### å°ç£é«˜è¡€å£“ç ”ç©¶

1. **Hung, M.-H., et al. (2021).** Prediction of Masked Hypertension and Masked Uncontrolled Hypertension Using Machine Learning. *Frontiers in Cardiovascular Medicine*, 8:778306. DOI: [10.3389/fcvm.2021.778306](https://doi.org/10.3389/fcvm.2021.778306)

2. **Chien, K.L., et al. (2011).** Prediction Models for the Risk of New Onset Hypertension in Ethnic Chinese in Taiwan. *Journal of Human Hypertension*, 25, 294â€“303.

### å°ç£ç³–å°¿ç—…ç ”ç©¶

3. **Liu, Y.-Q., et al. (2024).** Use of Machine Learning to Predict the Incidence of Type 2 Diabetes Among Relatively Healthy Adults: A 10-Year Longitudinal Study in Taiwan. *Diagnostics*, 15(1), 72. DOI: [10.3390/diagnostics15010072](https://doi.org/10.3390/diagnostics15010072) âœ…

4. **Dual Machine Learning Framework (2025).** Dual Machine Learning Framework for Predicting Long-Term Glycemic Change and Prediabetes Risk in Young Taiwanese Men. *Diagnostics*, 15(19), 2507. ğŸ“Œ

5. **Chen, C.-Y., & Huang, D.-Y. (2023).** Predicting the Onset of Diabetes with Machine Learning Methods. *Journal of Personalized Medicine*, 13(3), 406.

### å°ç£ä»£è¬ç—‡å€™ç¾¤ç ”ç©¶

6. **An Application of Metabolic Syndrome Severity Scores in the Lifestyle Risk Assessment of Taiwanese Adults (2020).** *International Journal of Environmental Research and Public Health*, 17(10), 3348.

7. **A Data-Driven Assessment of the Metabolic Syndrome Criteria for Adult Health Management in Taiwan (2019).** *International Journal of Environmental Research and Public Health*, 16(1), 92.

### å°ç£è¡€è„‚æŒ‡å¼•

8. **Huang, P.-H., et al. (2022).** 2022 Taiwan lipid guidelines for primary prevention. *Journal of the Formosan Medical Association*, 121(12), 2393-2407.

### åœ‹éš›ç ”ç©¶ï¼ˆæ–¹æ³•è«–åƒè€ƒï¼‰

9. **Predicting dyslipidemia incidence: unleashing machine learning algorithms on Lifestyle Promotion Project data (2024).** *BMC Public Health*.

10. **Machine learning-based prediction of LDL cholesterol (2025).** Various international studies.

---

## ä¹ã€ä¸‹ä¸€æ­¥è¡Œå‹•

### Meeting 17 æº–å‚™

#### å„ªå…ˆä»»å‹™

1. **æ·±å…¥ç ”ç©¶ Dual Framework 2025** ğŸ“Œ
   - ä¸‹è¼‰ä¸¦é–±è®€å®Œæ•´è«–æ–‡
   - åˆ†æ Î´-FPGï¼ˆè¡€ç³–è®ŠåŒ–é‡ï¼‰ç‰¹å¾µå·¥ç¨‹æ–¹æ³•
   - ç ”ç©¶é›™æ¡†æ¶è¨­è¨ˆï¼ˆé€£çºŒå€¼é æ¸¬ + åˆ†é¡ï¼‰
   - å­¸ç¿’ SHAP è§£é‡‹æ€§æ‡‰ç”¨

2. **æ·±å…¥åˆ†æ Hung et al. 2021** âš ï¸
   - é–±è®€å·²ä¸‹è¼‰çš„ PDF
   - åˆ†æç‰¹å¾µé¸æ“‡æ–¹æ³•ï¼ˆå¦‚ä½•å¾33å€‹æ¸›å°‘åˆ°6å€‹ï¼‰
   - ç ”ç©¶å¤–éƒ¨é©—è­‰ç­–ç•¥
   - æ•´ç†é«˜è¡€å£“é æ¸¬çš„é—œéµç‰¹å¾µ

#### æ¬¡è¦ä»»å‹™

3. æ•´ç†ä¸‰é«˜é æ¸¬çš„å…±åŒç‰¹å¾µ
4. æ¯”è¼ƒä¸åŒç ”ç©¶çš„è³‡æ–™è™•ç†æ–¹æ³•
5. æº–å‚™æ–‡ç»æ¯”è¼ƒè¡¨æ ¼ï¼ˆç”¨æ–¼è«–æ–‡ Literature Review ç« ç¯€ï¼‰

---

**æ–‡æª”å»ºç«‹æ—¥æœŸ**ï¼š2025å¹´
**æœ€å¾Œæ›´æ–°**ï¼š2025-11-11
**ç¶­è­·è€…**ï¼šç´€ä¼¯å–¬

---

## ğŸ“Œ å¿«é€Ÿå°èˆª

- ğŸ“‚ [è¿”å›ç ”ç©¶è¨ˆç•«ç›®éŒ„](.)
- ğŸ“– [æŸ¥çœ‹ç³»çµ±æ€§æ–‡ç»å›é¡§](../literature_notes/Systematic_Literature_Review.md)
- ğŸ“Š [æŸ¥çœ‹ Meeting 1-16 ç¸½çµ](../meeting_notes/Meeting_Summary_1-16.md)
- ğŸ¯ [æŸ¥çœ‹å°ˆæ¡ˆ README](../../README.md)
